Ikarian Capital, LLC Avadel Pharmaceuticals PLC Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$6.61 - $10.07 $361,527 - $550,768	-54,694 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$5.02 - $8.98 $2.17 Million - $3.88 Million	-432,449 Reduced 88.77%	54,694 $275,000
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $2.94 Million - $4.76 Million	405,000 Added 493.04%	487,143 $3.94 Million
Q1 2020 May 15, 2020	BUY	$4.06 - $10.64 $333,500 - $874,001	82,143 New	82,143 $652,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.